Answers are grounded in this paper and cite their sources.
Emicizumab prophylaxis can be successfully managed during dual antiplatelet therapy for drug-eluting stent insertion after acute coronary syndrome.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nagao et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: